157 related articles for article (PubMed ID: 18086345)
1. Clinical management of T-cell malignancies: current perspectives, key issues, and emerging therapies.
Cheson BD
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S3-7. PubMed ID: 18086345
[TBL] [Abstract][Full Text] [Related]
2. New drug therapies in peripheral T-cell lymphoma.
Howman RA; Prince HM
Expert Rev Anticancer Ther; 2011 Mar; 11(3):457-72. PubMed ID: 21417858
[TBL] [Abstract][Full Text] [Related]
3. Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.
Cheson BD
Curr Opin Hematol; 2009 Jul; 16(4):299-305. PubMed ID: 19367159
[TBL] [Abstract][Full Text] [Related]
4. Novel agents in development for peripheral T-cell lymphoma.
O'Connor OA
Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan.
Tobinai K
Semin Hematol; 2010 Apr; 47 Suppl 1():S5-7. PubMed ID: 20359583
[TBL] [Abstract][Full Text] [Related]
6. Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL).
Dummer R
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S33-6. PubMed ID: 16516674
[TBL] [Abstract][Full Text] [Related]
7. Nelarabine: a novel purine antimetabolite antineoplastic agent.
Buie LW; Epstein SS; Lindley CM
Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
[TBL] [Abstract][Full Text] [Related]
8. Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma.
Walker PL; Dang NH
Clin J Oncol Nurs; 2004 Apr; 8(2):169-74. PubMed ID: 15108419
[TBL] [Abstract][Full Text] [Related]
9. Mycosis fungoides: pathophysiology and emerging therapies.
Duvic M; Foss FM
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S21-8. PubMed ID: 18086343
[TBL] [Abstract][Full Text] [Related]
10. CD26: a novel treatment target for T-cell lymphoid malignancies? (Review).
Sato K; Dang NH
Int J Oncol; 2003 Mar; 22(3):481-97. PubMed ID: 12579300
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapies for B-cell non-Hodgkin lymphoma.
Briones J
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1305-16. PubMed ID: 19761434
[TBL] [Abstract][Full Text] [Related]
12. Denileukin diftitox: a novel immunotoxin.
Manoukian G; Hagemeister F
Expert Opin Biol Ther; 2009 Nov; 9(11):1445-51. PubMed ID: 19817678
[TBL] [Abstract][Full Text] [Related]
13. Therapy options in cutaneous T-cell lymphoma.
Apisarnthanarax N; Duvic M
Expert Rev Anticancer Ther; 2001 Oct; 1(3):403-20. PubMed ID: 12113107
[TBL] [Abstract][Full Text] [Related]
14. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
Galmarini CM
IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
[TBL] [Abstract][Full Text] [Related]
15. Cladribine for the treatment of indolent non-Hodgkin's lymphomas.
Hoffman MA
Semin Hematol; 1996 Jan; 33(1 Suppl 1):40-4. PubMed ID: 8714616
[No Abstract] [Full Text] [Related]
16. Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.
Delmonte A; Ghielmini M; Sessa C
Oncologist; 2009 May; 14(5):511-25. PubMed ID: 19411316
[TBL] [Abstract][Full Text] [Related]
17. Management of peripheral T-cell non-Hodgkin's lymphoma.
Horwitz SM
Curr Opin Oncol; 2007 Sep; 19(5):438-43. PubMed ID: 17762567
[TBL] [Abstract][Full Text] [Related]
18. Salvage therapy in Hodgkin's lymphoma.
Mendler JH; Friedberg JW
Oncologist; 2009 Apr; 14(4):425-32. PubMed ID: 19342476
[TBL] [Abstract][Full Text] [Related]
19. Purine nucleoside phosphorylase inhibitors in T-cell malignancies.
Bantia S; Kilpatrick JM
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):243-7. PubMed ID: 15603259
[TBL] [Abstract][Full Text] [Related]
20. Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies.
Molina JR
IDrugs; 2008 Jul; 11(7):508-21. PubMed ID: 18600598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
